Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | TP53 wild-type |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03107780 | Phase I | KRT-232 | Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | Terminated | USA | 0 |
| NCT02842125 | Phase I | Ad5CMV-p53 gene + Pembrolizumab Ad5CMV-p53 gene + Capecitabine Ad5CMV-p53 gene + Nivolumab | Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer | Terminated | USA | 0 |
| NCT03041688 | Phase I | Decitabine + KRT-232 + Venetoclax | Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT03725436 | Phase I | ALRN-6924 + Paclitaxel | ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors | Active, not recruiting | USA | 0 |
| NCT04669067 | Phase Ib/II | KRT-232 + TL-895 | TL-895 and KRT-232 Study in Acute Myeloid Leukemia | Unknown status | USA | ITA | FRA | ESP | DEU | AUT | AUS | 1 |
| NCT06084689 | Phase II | BI 907828 + Ezabenlimab | Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid Structures (EMPIRE) | Withdrawn | FRA | 0 |
| NCT04190550 | Phase I | Cytarabine + Idarubicin + KRT-232 | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
| NCT01760525 | Phase I | CGM097 | A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors | Completed | USA | FRA | DEU | CHE | 1 |
| NCT03654716 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer | Completed | USA | 0 |
| NCT01914900 | Phase II | Cisplatin + Docetaxel + Fluorouracil | Preoperative TPF Chemotherapy in a Population of Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer | Completed | ITA | 0 |
| NCT03975387 | Phase Ib/II | ASTX295 | Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53 | Terminated | USA | 0 |
| NCT02264613 | Phase Ib/II | ALRN-6924 | Safety Study of ALRN-6924 in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04502394 | Phase Ib/II | Acalabrutinib + KRT-232 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | Unknown status | USA | POL | ITA | GBR | FRA | CZE | CHE | BEL | AUS | 2 |
| NCT02143635 | Phase I | Siremadlin | Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt | Completed | USA | NLD | FRA | ESP | DEU | 3 |
| NCT05797831 | Phase II | KRT-232 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | Recruiting | USA | SWE | SVN | ROU | POL | NOR | LTU | ITA | ISR | HUN | FIN | EST | ESP | DNK | CAN | AUT | 1 |
| NCT03714958 | Phase I | Siremadlin + Trametinib | Trametinib + HDM201 in CRC Patients With RAS/RAF Mutant and TP53 Wild-type Advanced/Metastatic Colorectal Cancer Mutant and TP53 Wild-type (TRAHD) | Completed | FRA | 0 |
| NCT03964233 | Phase I | BI 907828 + Ezabenlimab + Miptenalimab BI 907828 + Ezabenlimab | A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) | Active, not recruiting | USA | NLD | HUN | GBR | FRA | ESP | DEU | BEL | AUS | 2 |
| NCT03560882 | Phase I | Atorvastatin | A Pilot Trial of Atorvastatin in Tumor Protein 53 (p53) -Mutant and p53 Wild-Type Malignancies | Active, not recruiting | USA | 0 |
| NCT03940352 | Phase I | Siremadlin + Venetoclax Sabatolimab + Siremadlin | HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Terminated | USA | ITA | FIN | ESP | DEU | AUS | 1 |
| NCT04835584 | Phase Ib/II | Dasatinib + KRT-232 KRT-232 + Nilotinib | KRT-232 and TKI Study in Chronic Myeloid Leukemia | Recruiting | USA | POL | ITA | FRA | ESP | CAN | 2 |
| NCT02909972 | Phase I | ALRN-6924 + Cytarabine ALRN-6924 | Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome | Completed | USA | 0 |